Fresenius will cooperate with a Chinese company for the development of biosimilars: the decision will increase the sales of original drugs by more than 414 billion dollars. The German technology and medical concern Fresenius announced an agreement with the Chinese company WuXi Biologics for the joint development of biosimilars. Under the terms of the deal, Fresenius will have exclusive access to 37 identified biosimilar candidates over the next decade. This decision will help the concern to increase sales of original drugs by more than 414 billion dollars. Fresenius plans that working together with developers from China will help increase the number of molecules from 29 to 66 by the next decade. The range covers 13 therapeutic areas and includes monoclonal and bispecific antibodies, antibody-drug conjugates and fusion proteins. Read us in Max Telegram VK.

Fresenius will cooperate with a Chinese company for the development of biosimilars: the decision will increase the sales of original drugs by more than 414 billion dollars. The German technology and medical concern Fresenius announced an agreement with the Chinese company WuXi Biologics for the joint development of biosimilars. Under the terms of the deal, Fresenius will have exclusive access to 37 identified biosimilar candidates over the next decade. This decision will help the concern to increase sales of original drugs by more than 414 billion dollars. Fresenius plans that working together with developers from China will help increase the number of molecules from 29 to 66 by the next decade. The range covers 13 therapeutic areas and includes monoclonal and bispecific antibodies, antibody-drug conjugates and fusion proteins. Read us in Max Telegram VK.